UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000012502
Receipt number R000013926
Scientific Title Protective efficacy of the prochlorperazine for oxycodone-induced nausea and vomiting for patients with cancer pain Randomized placebo control double-blind trial (phase III study)
Date of disclosure of the study information 2013/12/05
Last modified on 2016/12/07 23:29:06

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Protective efficacy of the prochlorperazine for oxycodone-induced nausea and vomiting for patients with cancer pain
Randomized placebo control double-blind trial (phase III study)

Acronym

POINT study

Scientific Title

Protective efficacy of the prochlorperazine for oxycodone-induced nausea and vomiting for patients with cancer pain
Randomized placebo control double-blind trial (phase III study)

Scientific Title:Acronym

POINT study

Region

Japan


Condition

Condition

Cancer pain

Classification by specialty

Not applicable Adult

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

In the patients with cancer pain, we evaluate the advantage for the placebo group of the prochlorperazine by a placebo-controlled double-blind randomized controlled trial for the prevention of oxycodone-induced nausea, vomiting.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The primary outcome set nausea during study period with complete response rate (CR rate) of the vomiting-related event.
"There was not a vomiting-related event" and defined it as the patients that "there was not relief treatment for nausea" with CR.

Key secondary outcomes

(1)
Time of onset until an initial "vomiting-related event"
The time when the first "vomiting-related event" developed from study drug initiation
(2)
Time before using antiemetics rescue from study drug initiation for the first time at the first time to "antiemetics relief treatment"
(3)
"There is no vomiting-related event"; population of patients
Ratio of patients that there was not "a vomiting-related event" during study period
(4)
The number of times of "the vomiting-related event"
We assume "a vomiting-related event" 1 episode and count 1 episode with once.
However, we include it in 1 episode when we show a similar vomiting-related event within five minutes.
(5)
"There is no nausea"; population of patients
Ratio of patients of "(for the patients of study initiation time CTC-AE Grade1) whom "there is no nausea" after study drug initiation or there is no exacerbation of nausea" in
(6)
Degree of "nausea"
We evaluate severest "nausea" in NRS every 24 hours and evaluate it on average of 5 days.
(7)
Ratio of patients who "there was no antiemetics relief treatment", and did not use population of patients antiemetics rescue
(8)
The number of times of "the antiemetics relief treatment"
Use of the antiemetics rescue
(9)
Consumption of opioids
Gross weight (including the relief treatment) of the opioids which we used
(10)
Change of the quantity of diet
(11)
Quality of life evaluation
We evaluate it in EORTC QLQ-C15-PAL.
(12)
Adverse event


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

The study drug group assumes prochlor perazine(5 mg of Novamin locks) internal use after a meal three times a day for five days.

Interventions/Control_2

Placebo assumes placebo internal use after a meal three times a day for five days.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <

Age-upper limit

100 years-old >

Gender

Male and Female

Key inclusion criteria

(1)Patients with cancer that the internal use of the oxycodone is necessary for treatment of cancer pain
(2)
It is expected that internal use of the oral medication can maintain a possible state for one week
(3)
We are 20 years old or older
(4)
A document agreement by the free will of the patients person himself is obtained in the thing which understands it enough after having received enough explanation on participating of this study
(5)
Survival one month or more is expected from a registration day
(6)
The latest laboratory values within one month before registration meet the following criteria
1)
5 times * 1 of the AST(GOT) <= institution reference value
2)
5 times * 1 of the ALT (GPT) <= institution reference value
*
When we judge it including the patients with 1 liver metastasis and the patients with biliary system tumor including the pancreatic cancer when a medical attendant is suitable when it is a reference value or more, the registration is possible.
However, it is assumed that, in that case, it is Grade3 or less in CTC-AE.
3)
Creatinine clearance >= 30ml/min( calculated value or actual value) * 2
*
Male Ccr (ml/min)= weight (kg) X (140-age) / (72* serum creatinine (mg/dl)) which is carried out using expression of Cockcroft-Gault about the calculated value of 2 creatinine clearance
)
Female Ccr (ml/min)= men Ccr *0.85
4)
3 times of the total bilirubin levels <= institution reference value

Key exclusion criteria

(1)PS (performance status) 4 patients) of ECOG(Eastern Cooperative Oncology Group)
(2)The patients whom condition is unstable in for digestive system disease (including reflux oesophagitis, a gastric ulcer, gastrointestinal obstruction, constipation)
(3)There is the electrolyte abnormality with "nausea (CTC-AE Grade2 )" or "the vomiting-related event" the patients
(4)With "nausea (CTC-AE Grade2 )" or "the vomiting-related event" by other causes the patients
(5)The patients with a symptomatic central nerve lesion (including brain metastasis, cancer-related meningitis)
(6)We correct the patients who they received head, abdomen (it is assumed that it is lower than diaphragm) or pelvic radiotherapy during - study period six days ago or are going to receive it with study drug initiation, and, as for the localized radiotherapy, combination is possible on the bone part with bone metastases
(7)Within 48 hours before study drug initiation, it is the patients using the drug (including a digitalis, the chalybeate) with the emetic action.
However, it is excluded when we use it regularly for more than study drug initiation one week
(8)Within 48 hours before study drug initiation, it is the patients using the drug with the antiemetic activity.
(9)It is the patients who used a medical drug in treatment regularly with cancer pain within three months before registration.
(10)It is the patients with a history of hypersensitivity to a prochlorperazine
(11)Patients to be contraindicated to prochlorperazine
(12)It is the patients with a history of QTc prolongation (QTc> 470msec) with a past electrocardiogram.
However, when there is no QTc prolongation in the electrocardiogram within three months before registration, registration is possible
(13)The patients with other serious complications
(14)Within one week before study drug initiation, it is the patients using an anticancer drug or the molecular target medicine with non-administration in the past

Target sample size

120


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yuichi Ando

Organization

Nagoya University Hospital

Division name

Department of Clinical Oncology and Chemotherapy

Zip code


Address

65, Tsurumaicho, Syowa-ku, Nagoya-shi, Aichi

TEL

0527441902

Email

yando@med.nagoya-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Hiroaki Tsukuura

Organization

Nagoya University Hospital

Division name

Department of Clinical Oncology and Chemotherapy

Zip code


Address

65, Tsurumaicho, Syowa-ku, Nagoya-shi, Aichi

TEL

0527441902

Homepage URL


Email

tsuku@med.nagoya-u.ac.jp


Sponsor or person

Institute

Nagoya University Hospital Department of Clinical Oncology and Chemotherapy

Institute

Department

Personal name



Funding Source

Organization

Nagoya University Hospital Department of Clinical Oncology and Chemotherapy

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)

Grant for Research Advancement on Palliative Medicine, Japanese Society for Palliative Medicine


IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

名古屋大学医学部附属病院


Other administrative information

Date of disclosure of the study information

2013 Year 12 Month 05 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2013 Year 11 Month 11 Day

Date of IRB


Anticipated trial start date

2013 Year 12 Month 16 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2013 Year 12 Month 05 Day

Last modified on

2016 Year 12 Month 07 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000013926


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name